{"id":634349,"date":"2023-01-17T16:16:01","date_gmt":"2023-01-17T16:16:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=634349"},"modified":"2023-01-17T16:16:01","modified_gmt":"2023-01-17T16:16:01","slug":"cytokine-release-syndrome-clinical-trials-a-drug-pipeline-analysis-report-2023-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/cytokine-release-syndrome-clinical-trials-a-drug-pipeline-analysis-report-2023-delveinsight_634349.html","title":{"rendered":"Cytokine Release Syndrome Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1673936274.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Cytokine Release Syndrome Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1673936274.jpeg\" alt=\"Cytokine Release Syndrome Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Cytokine Release Syndrome Pipeline Insights<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s, \u201cCytokine Release Syndrome \u2013 Pipeline Insight, 2023,\u201d report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Cytokine Release Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s <strong>&#8216;<\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cytokine-release-syndrome-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\"><strong>Cytokine Release Syndrome Pipeline Insight 2023<\/strong><\/a><strong>&#8216;<\/strong> report provides comprehensive global coverage of available, marketed, and pipeline Cytokine Release Syndrome therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Cytokine Release Syndrome pipeline domain.<\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/cytokine-release-syndrome-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\">Cytokine Release Syndrome Pipeline Report<\/a><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Over 5+ Cytokine Release Syndrome pipeline therapies are in various stages of development, and their anticipated acceptance in the Cytokine Release Syndrome market would significantly increase market revenue.&nbsp;<\/li>\n<li>Leading Cytokine Release Syndrome companies developing novel drug candidates to improve the Cytokine Release Syndrome treatment landscape include<strong> Novartis, Incyte Corporation, Olatec Therapeutics LLC, <\/strong>and others.<\/li>\n<li>Promising Cytokine Release Syndrome pipeline therapies in various stages of development include<strong> Canakinumab<\/strong>, <strong>Itacitinib<\/strong>, <strong>Dapansutrile<\/strong>, and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Cytokine Release Syndrome Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Cytokine release syndrome (CRS) happens when your immune system responds more aggressively to infection or immunotherapy drugs than it should. CRS symptoms include fever, nausea, fatigue and body aches. Prompt treatment is essential, as symptoms can worsen quickly.<\/p>\n<p style=\"text-align: justify;\"><strong>Cytokine Release Syndrome Pipeline Analysis: Drug Profile<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Canakinumab: Novartis<\/strong><\/p>\n<p style=\"text-align: justify;\">Canakinumab is an interleukin (IL)-1&beta; blocker indicated to treat certain periodic fever syndromes, such as cryopyrin-associated periodic syndromes and systemic juvenile idiopathic arthritis. Novartis is conducting phase III trial, called CAN-COVID which will evaluate the drug&rsquo;s efficacy in treating a type of severe immune overreaction called cytokine release syndrome (CRS) related to Covid-19 pneumonia.<\/p>\n<p style=\"text-align: justify;\">Discover more about the emerging Cytokine Release Syndrome drugs @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cytokine-release-syndrome-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\"><strong>Cytokine Release Syndrome Treatment Drugs<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong>Cytokine Release Syndrome Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Novartis<\/li>\n<li>Incyte Corporation<\/li>\n<li>Olatec Therapeutics LLC<\/li>\n<li>And others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Cytokine Release Syndrome Pipeline Therapies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Canakinumab<\/li>\n<li>Itacitinib<\/li>\n<li>Dapansutrile<\/li>\n<li>And others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Cytokine Release Syndrome Pipeline Therapeutics Assessment<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>By development stage<\/strong><\/li>\n<li><strong>By product type<\/strong><\/li>\n<li><strong>By route of administration<\/strong><\/li>\n<li><strong>By molecule type<\/strong><\/li>\n<li><strong>By MOA type&nbsp;<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Scope of the Cytokine Release Syndrome Pipeline Report&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Coverage<\/strong>:&nbsp;Global&nbsp;<\/li>\n<li><strong>Key Cytokine Release Syndrome Companies<\/strong>: Novartis, Incyte Corporation, Olatec Therapeutics LLC, and others<\/li>\n<li><strong>Key Cytokine Release Syndrome Pipeline Therapies<\/strong>: Canakinumab, Itacitinib, Dapansutrile, and others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Find out more about the Cytokine Release Syndrome treatment options in development @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cytokine-release-syndrome-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\"><strong>Cytokine Release Syndrome Clinical Trials<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. Overview<\/p>\n<p style=\"text-align: justify;\">4. Pipeline Therapeutics<\/p>\n<p style=\"text-align: justify;\">5. Late-Stage Products (Phase III)<\/p>\n<p style=\"text-align: justify;\">6. Mid-Stage Products (Phase&nbsp; II)<\/p>\n<p style=\"text-align: justify;\">7. Early Stage Products (Phase&nbsp; I\/II)<\/p>\n<p style=\"text-align: justify;\">8. Preclinical Stage Products<\/p>\n<p style=\"text-align: justify;\">9. Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\">10. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">11. Inactive Products<\/p>\n<p style=\"text-align: justify;\">12. Collaborations Assessment- Licensing \/ Partnering \/ Funding<\/p>\n<p style=\"text-align: justify;\">13. Unmet Needs<\/p>\n<p style=\"text-align: justify;\">14. Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\">15. Appendix<\/p>\n<p style=\"text-align: justify;\">16. About DelveInsight<\/p>\n<p style=\"text-align: justify;\"><strong>Request for a sample report to know more about the leading companies in the&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/cytokine-release-syndrome-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\">Cytokine Release Syndrome pipeline segment<\/a>.<\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=cytokine-release-syndrome-clinical-trials-a-drug-pipeline-analysis-report-2023-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=cytokine-release-syndrome-clinical-trials-a-drug-pipeline-analysis-report-2023-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cytokine Release Syndrome Pipeline Insights DelveInsight\u2019s, \u201cCytokine Release Syndrome \u2013 Pipeline Insight, 2023,\u201d report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Cytokine Release Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/cytokine-release-syndrome-clinical-trials-a-drug-pipeline-analysis-report-2023-delveinsight_634349.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-634349","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/634349","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=634349"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/634349\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=634349"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=634349"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=634349"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}